Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants.: HP40-308/2022E-1-PDF
"The objective of this advisory committee statement is to review evidence and develop guidance on strategies to prevent severe consequences of RSV infection in children at high risk of severe RSV disease by administration of monoclonal antibody"--Guidance objective, page 8.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.913694&sl=0
| Department/Agency | Canada. National Advisory Committee on Immunization, issuing body. |
|---|---|
| Title | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Earlier edition | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
| Format | Electronic |
| Electronic document | |
| Note(s) | Cover title. "Publication date: June 2022." Publication copy replaced 2022-12-12 at request of authors. At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Issued also in French under title: Utilisation recommandée du palivizumab pour réduire les complications de l'infection par le virus respiratoire syncytial chez les nourrissons. Includes bibliographical references (pages 76-97). |
| Publishing information | [Ottawa] : Public Health Agency of Canada = Agence de la santé publique du Canada, 2022. ©2022 |
| Description | 1 online resource (151 pages) |
| ISBN | 9780660447117 |
| Catalogue number |
|
| Departmental catalogue number | 220345 |
| Subject terms | Palivizumab -- Canada. Respiratory syncytial virus -- Canada. Infants -- Diseases -- Canada. |